Other Products → LIPOLYSIS
WEGOVY
Semaglutide (0.25 mg / 0.5 mg / 1 mg / 1.7 mg / 2.4 mg)
WEGOVY® is a once-weekly prescription medicine containing semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk for chronic weight management alongside diet and physical activity.
Categories
+
Effects
+
Supports weight loss and long-term weight management by regulating appetite, increasing satiety, reducing hunger, and helping decrease food intake.
SPEC
+
1 Pen
Content
+
Active Ingredient: Semaglutide
Available Doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg
Once-weekly subcutaneous injection
1 pre-filled pen per box
4 disposable needles per box
Price
+
Pricing may vary depending on the destination country, order quantity, and business requirements. Our sales team is ready to assist you with current pricing and availability. Feel free to contact us anytime.
